FDA approves Spravato, first monotherapy nasal spray to treat depression
The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.
San Francisco Examiner1d
FDA Approves Spravato Nasal Spray for Treatment-Resistant Depression
The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major ...
Hosted on MSN15h
FDA approves Spravato, nasal spray derived from Ketamine
The FDA approves Spravato, a nasal spray derived from Ketamine, to help some people treat depression. Dr. Bill Hartman from UW Health shares more.
Healio1d
FDA approves Spravato as monotherapy for adults with major depressive disorder
The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as ...
FiercePharma2d
Johnson & Johnson's Spravato gains FDA nod to be used as a monotherapy
Already on its way to becoming a blockbuster drug, Johnson & Johnson’s Spravato has received another potential boost as the ...
Managed Healthcare Executive2d
FDA Approves Spravato Nasal Spray as a Standalone Treatment for Major Depressive Disorder
One-third of folks with major depressive disorder experience treatment-resistant depression (TRD), a condition that makes it ...
WXYZ1d
FDA approves Spravato as first stand-along nasal spray to treat drug-resistant depression
In today's Health Alert, the FDA has approved the first stand-alone nasal spray to treat drug-resistant depression.
WUNC2d
FDA allows standalone use of nasal spray antidepressant Spravato (esketamine)
The FDA says esketamine, an antidepressant derived from the anesthetic and party drug ketamine, can now be prescribed on its ...
Hosted on MSN1d
FDA Approves ‘Spravato’ Nasal Spray As A Standalone Depression Treatment
We have made great strides in the medical community, with people having access to life-saving physical drugs as well as ...
NBC Connecticut3d
FDA approves Johnson & Johnson's nasal spray for depression as standalone treatment
Spravato's long road to rapid growth Spravato blazed a new trail in 2019 as the first new major depression treatment to win FDA approval in more than three decades. The drug is related to ketamine ...
fox6now2d
FDA approves first-of-its-kind nasal spray to treat depression
The Food and Drug Administration (FDA) approved Johnson & Johnson's ketamine-derived nasal spray to help millions of U.S. patients suffering from severe depression. Spravato, approved as a ...
Reuters2d
Future of Health
Spravato, to allow it to be used as a standalone treatment for patients with severe depression, the company said on Tuesday. Healthcare & Pharmaceuticalscategory Outgoing FDA chief flags online ...